RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cartesian Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.08−0.19 (-3.03%)
Close on Oct 19, 2026
- Market cap
- $181.55M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.93 (−32.52%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Cartesian Therapeutics, Inc. reported revenue of $1.48M for the twelve months to Jun 30, 2026. Free cash flow was -$78.61M.
Revenue
$1.48M
TTM Q2 2026
Operating income
-$155.36M
TTM Q2 2026
Free cash flow
-$78.61M
TTM Q2 2026
EPS, diluted
-$5.94
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $181.55M
- P/E ratio
- –
- Price to sales
- 122.92
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -43.30%
Fundamentals
- Revenue
- $1.48M
- Net income
- -$151.89M
- EPS, diluted
- -$5.94
- Free cash flow
- -$78.61M
- Book value per share
- -$4.19
- Diluted shares
- 30M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$1.48M
Operating income
-$155.36M
Net income
-$151.89M
EPS, diluted
-$5.94
Free cash flow
-$78.61M
Reported periodTrailing twelve months